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Abstract
Transforming growth factor b1( TGFB1) T29C and TGF b receptor type 1 (TGFBR1) 6A/9A polymorphisms have been
implicated in the modulation of risk for breast cancer in Caucasian women. We analyzed these polymorphisms and
combinations of their genotypes, in pre menopausal breast cancer patients (N=182) and healthy women (N=236) from
western India as well as in breast cancer patients and healthy women from the Parsi community (N=48 & 171, respectively).
Western Indian women were characterized by a higher frequency of TGFB1*C allele of the TGF b T29C polymorphism (0.48 vs
0.44) and a significantly lower frequency of TGFBR1*6A allele of the TGFBR1 6A/9A polymorphism (0.02 vs 0.068, p,0.01) as
compared to healthy Parsi women. A strong protective effect of TGFB1*29C allele was seen in younger western Indian
women (,40 yrs; OR=0.45, 95% CI 0.25–0.81). Compared to healthy women, the strikingly higher frequencies of low or
intermediate TGF b signalers in patients suggested a strong influence of the combination of these genotypes on the risk for
breast cancer in Parsi women (for intermediate signalers, OR=4.47 95%CI 1.01–19.69). The frequency of low signalers in
Parsi healthy women, while comparable to that reported in Europeans and Americans, was three times higher than that in
healthy women from western India (10.6% vs 3.3%, p,0.01). These observations, in conjunction with the low incidence rate
of breast cancer in Indian women compared to White women, raise a possibility that the higher frequency of TGFB1*29C
allele and lower frequency of TGFBR1*6A allele may represent important genetic determinants that together contribute to a
lower risk of breast cancer in western Indian women.
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Introduction
Germline mutations in various cancer susceptibility genes can
account for only around 10% of all breast cancer cases [1]. Thus,
the genetic basis of breast cancer in the majority of patients who do
not have a family history for malignant disorders remains poorly
understood. The influence of common genetic variants on the risk
for breast cancer has been suggested by many studies [2,3]. The
identification of a number of such variants in recent years highlights
the interest and efforts in this direction [4,5]. These efforts could aid
in population based screening to identify high risk subjects [6]. In
this context, the naturally occurring functional polymorphisms in
TGF b1 and TGF b Receptor1 genes have been extensively studied
for their influence on the risk for various malignant disorders [4,7–
9]. The effect of modulation of TGF b1 expression on the growth of
mammary tumors in murine models [10,11], contribution of
mutations in genes coding for members of the TGF b signaling
pathway to the development or progression of various cancers
[12,13], and the association of higher levels of TGF b1 in tumor
tissues with lymph node metastases as well as poor prognosis
[14,15], all provide a strong rationale for such studies.
In breast cancer patients, TGFB1 T29C (L10P; rs1800470) and
TGFBR1 6A/9A remain the two most extensively studied
polymorphisms. In TGFB1 T29C polymorphism, a replacement
of Leucine by Proline at position 29 (TGFB1 codon10 T.C) has
been shown to result in an increased secretion of the cytokine [16].
A nine base pair deletion in the repeat sequence of exon 1 of the
TGFBR1 gene, giving rise to the TGFBR1*6A allele [17], was
found to result in weaker cytokine induced response compared to
the wild type, TGFBR1*9A allele [18]. The hypomorphic behavior
of this allele was also reflected in its association with weaker
radiation induced response of lymphocytes [19]. Moreover, the
allele has been implicated in TGF b independent enhancement of
migration and invasion of MCF-7 cells [20].
With regard to the risk for breast cancer, it has been proposed
that the presence of TGFB129*C allele that is associated with
higher production of the cytokine, would provide protection in the
initial stages by virtue of its anti-proliferative action on mammary
epithelial cells but would enhance the risk at later stages by
promoting invasion as well as spread of the disease [21]. Findings
of the Breast Cancer Association Consortium, the only large scale
study that has clearly addressed this possibility, favor such a
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risk of the disease [4]. Similar observations have been reported in
studies on European women [16]. Two recent meta analyses of
studies on population based controls [7,8] also arrived at the same
conclusion. On the other hand, some studies have failed to detect
any association [22–25] or have reported a weak protective
influence of TGFB1*CC genotype in older American women and
pre menopausal Japanese women [26,27]. Probable age and
ethnicity related variations within and across the study populations
are thought to be responsible for the discordant data. Similar
considerations may also explain the discordance between the
findings of various studies examining the influence of TGBR1 6A/
9A polymorphism on the risk for breast cancer [18,24,25,28,29].
However, a recent meta analysis supported the increased breast
cancer risk in women positive for the TGFBR1*6A allele [9]. The
trend of disagreement between observations from different studies
also extends to the study of the influence of the combined effect of
genotypes of these polymorphisms on the risk for breast cancer.
The larger impact of combinations of genotypes that result in weak
cytokine signaling leading to increased risk for the disease as
observed by Kaklamani et al [30], was not detected in two other
studies [24,25] suggesting a need for additional studies with larger
cohorts.
Population based data regarding these polymorphisms in Indian
women remains limited [31,32]. The increasing incidence of
breast cancer in the Indian subcontinent, especially in the younger
age group [33], emphasizes the need for studies addressing the
genetic basis of risk for breast cancer in the population. Further,
over forty percent of breast cancer patients in India are diagnosed
at age #45 years as against fifteen percent patients in western
countries, an observation supported by the trends reported in a
recent study [34]. We therefore examined the influence of TGF b1
T29C and TGFBR1 6A/9A gene polymorphisms in pre meno-
pausal women from western India. To that effect the study was
restricted to Marathi-speaking (Maharashtrian) subjects from
Western India, living within 200 km radius around the state-
capital city of Mumbai (who constitute 80% of the population of
the state of Maharashtra). In parallel, we have studied these
polymorphisms in breast cancer patients and healthy women from
the Parsi (Zoroastrian) community. Parsis in India represent a geo-
ethnically isolated community [35]. The advantages of genetic
studies in isolated populations have long been recognized [36].
Further, breast cancer is the most common cancer in Parsi women
with a 1.5 fold higher age adjusted incidence rate compared to the
rate in non-Parsi Indian women [37]. In view of these
considerations, it was of relevance to carry out a parallel study
in subjects from these two communities.
The comparison of genotypes in healthy subjects from the two
ethnically distinct communities studied, and the comparisons
between patients and healthy subjects within each of the groups
have revealed novel trends with significant implications. Further,
in terms of the influence of high TGF beta1 producing genotype
(TGFB1*CC) on the risk for breast cancer, our results reveal trends
that are opposite to those reported in Caucasian women. The basis
for these observations and their implications has been discussed
with due supporting literature.
To our knowledge, this is the first study of TGFBR1 6A/9A
genotypes in an Indian cohort. Similarly, this study also represents
the first report of combined analysis of these two polymorphisms in
populations outside the western hemisphere.
Materials and Methods
Study Subjects
Ethics Statement. This case-control study was carried out
with the approval of the ethics committee of the Tata Memorial
Hospital, Mumbai. The participants were recruited after obtaining
their informed, written consent.
Reproductive health history was collected with an appropriately
designed questionnaire. One hundred and eighty two Mahar-
ashtrian (Marathi-speaking, Hindu) pre menopausal women with
confirmed diagnosis of breast cancer treated at the Tata Memorial
Hospital during 1999–2005 were recruited within twelve to
eighteen months of diagnosis. Lack of family history for malignant
disorders could be confirmed for 75% of the cases. Two hundred
and thirty six unrelated, healthy premenopausal Maharashtrian
women without family history for cancer were recruited from the
community. Parsi women with breast cancer (N=48) comprised of
those treated in various hospitals in the city. Mean post diagnosis
duration for these patients was 4.864.2 yrs (Median =3), with
sixty two percent of the patients recruited within five years of
diagnosis. Healthy, unrelated Parsi women (N=171) were
recruited from the community. Eight Parsi patients as well as
ten healthy women volunteers reported a strong family history for
cancer.
The mean age was lower in healthy Maharashtrian controls
than in patients (33.167.5 and 39.166.6, respectively; p,0.01).
The available data indicated comparable age at menarche and
age at first child birth in the two groups (Table 1). In Parsi
subjects, the mean age of the control group was 57.169.2 yrs
Table 1. Reproductive health history of the study subjects.
Maharashtrian Subjects
*ab Parsi Subjects
$c-e
Controls Patients Controls Patients
N=236 N=182 N=171 N=48
Age 33.167.5
# 39.166.6 57.169.2 50.369
Age at Menarche 13.961.3 (190)
ˆ 14.763.5 (115) 12.761.6 (147) 12.961.7 (42)
Age at first child – birth 24.164.7 (136) 22.763.7 (90) 26.763.9 (125) 26.563.9 (36)
Age at Menopause - - 46.665.0 (131) 46.463.4 (29)
# (Mean 6 SD);ˆ Numbers in parentheses represent the number of subjects with available information. For patients, age represents age at diagnosis.
*a) Fifty three healthy subjects and six patients were unmarried; b) A number of young healthy subjects were recently married and hence nulliparous.
$ c) Twenty healthy subjects and ten patients were premenopausal; d) Sixteen healthy subjects and six patients were unmarried; e) Twenty six healthy women and five
patients were nulliparous.
doi:10.1371/journal.pone.0021866.t001
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menarche, first child birth and menopause was similar in the two
groups (Table 1).
Genotyping
Isolation of DNA for genotyping was carried out as described in
our earlier report [38]. Genotyping for TGFB1 T29C polymor-
phism was performed by PCR–SSP based method, using primers
described by Perrey et al [39]. Products were analyzed on 1.5%
agarose gel stained with ethidium bromide. DNA samples of known
genotypes from the International Histocompatibility Workshop Group
(IHWG) reference panel were used to validate the PCR conditions
and as controls in each experiment. Results were further confirmed
by DNA sequencing in representative samples. Genomic DNA was
amplified using primers, GAGGCCCTCCTACCTTTTG (F) and
GCAGCTTGGACAGGATCT (R) as described in the SNP
500 cancer database http://snp500cancer.nci.nih.gov/sequencing_
assays.cfm?snp_id=TGFB1-01. The amplified products were se-
quenced by the standard method using big dye terminator kit (ABI)
on 3100AVANT Genetic Analyzer (Applied Biosystems).
For TGFBR1 6A/9A genotyping, exon 1 of TGFBR1 was
amplified using primers described by Kaklamani et al [30]. Ten
microlitres reaction mix contained 50 ng of DNA, 1X PCR buffer
(Fermentas), 0.2 mM dNTPs, 1.5 mM Mg
2+, 10% DMSO, 0.1%
BSA and 0.5 units of Taq polymerase (Fermentas) along with
1.0 mM primers. PCR conditions were as follows 295uC for
5 min, 35 cycles of 94uC for 30 s, 65uC for 30 s, 72uC for 30 s,
followed by extension at 72uC for 5 min. PCR products (256/
247 bp) were analyzed on 2% agarose gel stained with ethidium
bromide. The genotypes were also confirmed by running the
products on 10% PAGE and by sequencing of representative
samples.
Statistical analysis
Chi-square test was used to find out if the genotype frequencies
in controls are in Hardy-Weinberg equilibrium and also to
determine the significance of difference in genotype frequencies
between different groups. For various comparisons, two sided p
values were calculated using Fisher’s exact test. To estimate the
risk for breast cancer, the frequencies of subjects homozygous for
the wild type alleles, namely TGFB1*29T and TGFBR1*9A, were
taken as reference for the respective polymorphisms. For
Maharashtrian subjects, the risk was determined after adjusting
for age, and was expressed as odds ratio with 95% confidence
interval. In each case, the odds ratios were computed for
dominant, additive and recessive models. Further, various
combinations of genotypes of these two polymorphisms were
categorized into high, intermediate and low signalers [30],
wherein subjects with TGFB1*CC and TGFBR1*9A/9A genotype
combination were identified as high signalers in accordance with
the high TGF b levels and strong TGFBR1 activity associated with
these genotypes. Individuals homozygous for the allele associated
with either higher TGF b levels or with strong signaling
(TGFB1*CC or TGFBR1*9A/9A) were grouped as intermediate
signalers, and subjects with the remaining combinations consti-
tuted low signalers. The risk was estimated for the latter two
groups with high signalers as reference. SPSS software (version
15.0) was used for statistical analysis. Power calculations were
performed using Quanto [40].
Results
Two hundred and twenty four healthy controls (95%) and one
hundred and sixty (88%) premenopausal breast cancer patients
from the Maharashtrian community could be genotyped for the
two polymorphisms studied. Similarly, one hundred and sixty
(94%) healthy Parsis and forty three Parsi patients (95%) could be
genotyped and included in the analysis. The genotype frequencies
for the two polymorphisms studied were in agreement with Hardy-
Weinberg equilibrium in healthy subjects from both the
communities.
Association of TGF b1 T29C polymorphism with risk for
breast cancer
The frequency of the variant allele (TGFB1*29C)i nh e a l t h y
Maharashtrian women was higher compared to that in healthy
Parsi women (0.48 vs 0.44; Table 2). The differences in
genotype frequencies between healthy Maharashtrian and Parsi
women were not statistically significant. In Parsis, genotype
frequencies differed significantly between healthy subjects and
patients (p=0.002; Table 2). The higher frequency of
TGFB1*TC genotype in Parsi patients was further confirmed
by sequencing 50% of the randomly selected samples. The
genotype frequencies were also analyzed in different subgroups
of Maharashtrian patients, based on age at diagnosis (, or
$40 yrs).
A trend towards a protective effect of TGFB129*C allele
(OR=0.66; CI, 0.42–1.02) was noted in Maharashtrian subjects
for the dominant model only (Table 3). In Parsi subjects, the
increased risk suggested in carriers of TGFB129*C allele (dominant
model) and a protective influence of the TGFB1*CC genotype
recessively, were not statistically significant (Table 3). In younger
Maharashtrian subjects, (,40 yrs), stronger protection observed in
carriers of the TGFB1*29C allele remained unaffected even after
adjustment for age (OR=0.50; CI, 0.27–0.94; Table 4). In the
same age group, subjects homozygous for the variant allele were
significantly protected compared to those homozygous for the wild
Table 2. Frequencies of TGFB1T29C and TGFBR1 6A/9A
genotypes in the study populations.
Maharashtrian
Subjects Parsi Subjects
Controls Cases Controls Cases
TGFB1 T29 C N (%) N (%) N (%) N (%)
TT 61 (27.2) 58 (36.2) 53 (33.1) 9 (20.9)*
TC 109 (48.7) 72 (45.0) 72 (45.0) 32 (74.4)
CC 54 (24.1) 30 (18.8) 35 (21.9) 2 (4.7)
T% 51.6 58.8 55.6 58
C% 48.4 41.2 44.4 42
TGFBR1 6A/9A N (%) N (%) N (%) N (%)
9A 213 (95.9) 163 (97.6) 148 (87.6) 33 (78.6)
9A6A 9 (4.1) 4 (2.4) 19 (11.2) 8 (19.0)
6A 0 0 2 (1.2) 1 (2.4)
9A% 98 98.8 93.2 88.1
6A% 2** 1.2 6.8 11.9
*p,0.01 for TGFB1 T29C genotype frequencies in Parsi healthy controls vs
patients.
**p,0.01 for TGFBR1*6A allele frequency in healthy Maharashtrian vs Parsi
women.
doi:10.1371/journal.pone.0021866.t002
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recessive model.
TGFBR1 6A/9A polymorphism and risk for breast cancer
table-2-captionThe distribution of genotype frequencies for the
TGFBR1 6A/9A polymorphism in Maharashtrian healthy women
was significantly different from that in Parsi healthy women
(p=0.006; Table 2). Maharashtrian patients and controls were
characterized by the absence of TGFBR1*6A homozygous
individuals and comparable frequencies of TGFBR1 6A/9A
genotypes. Risk assessment based on the observed genotype
frequencies was inconclusive in Parsis as well as Maharashtrians
(Table 5).
TGF b1 signaling strength in relation to the risk for breast
cancer
Analysis of combinations of the TGFB1 T29C and TGFBR1
6A/9A genotypes revealed significantly elevated frequency of low
signalers in healthy Parsi women compared to their Maharashtrian
counterparts (10.6% vs 3.2%; p,0.01; Table 6). The suggested
increased risk for the disease in intermediate signalers among
Maharashtrian women was not statistically significant (additive
model, Table 6). In Parsi women, the intermediate and low
signaling status conferred significantly higher risk for breast cancer
with OR of 4.47 (CI, 1.01–19.69; p=0.05) and 8.47 (CI 1.64–
43.72; p=0.01), respectively (Table 6). Higher risk for interme-
diate and low signalers was also seen for dominant as well as
Table 3. TGFB1 T29C polymorphism and risk for breast cancer in Maharashtrian and Parsi women.
Maharashtrian Subjects Parsi Subjects
Cases/Controls OR
{ (95% CI) OR
{ (95% CI) Cases/Controls OR
{ (95% CI)
Genotype
TGFB1*T29C
Dominant Model
TT 58/61 1 1 9/53 1
TC/CC 102/163 0.66 (0.42-1.02) 0.73 (0.46-1.17) 34/107 1.87 (0.84-4.19)
Additive Model
TT 58/61 1 1 9/53 1
TC 72/109 0.69 (0.44-1.11) 0.75 (0.46-1.24) 32/72 2.62 (1.15-5.94)
CC 30/54 0.58 (0.33-1.04) 0.68 (0.37-1.26) 2/35 0.34 (0.07-1.65)
Recessive Model
TT/TC 130/170 1 1 41/125 1
CC 30/54 0.73 (0.44-1.2) 0.8 (0.47-1.38) 2/35 0.17 (0.04-0.76)*
{Crude ORs;
{ Age adjusted ORs; *p,0.05.
doi:10.1371/journal.pone.0021866.t003
Table 4. TGFB1 T29C gene polymorphism and risk for breast cancer in Maharashtrian subjects with respect to the age of onset.
,40 yrs $40 yrs
Cases/Controls OR
{ (95% CI) OR
{ (95% CI) Cases/Controls OR
{ (95% CI) OR
{ (95% CI)
Genotype
TGFB1 T29C
Dominant Model
TT 29/39 1 1 29/22 1 1
TC/CC 41/123 0.45 (0.25-0.81)** 0.50 (0.27-0.94)* 61/40 1.16 (0.58-2.29) 1.17 (0.59-2.32)
Additive Model
TT 29/39 1 1 29/22 1 1
TC 30/79 0.51 (
0.27-0.97)*
0.56 (0.28-1.11) 42/30 1.06 (0.51-2.19) 1.08 (0.52-2.23)
CC 11/44 0.34 (0.15-0.76)** 0.39 (0.16-0.92)* 19/10 1.44 (0.56-3.71) 1.44 (0.56-3.71)
Recessive Model
TT/TC 59/118 1 1 71/52 1 1
CC 11/44 0.5 (0.24-1.04) 0.55 (0.25-1.18) 19/10 1.39 (0.59-3.24) 1.38 (0.59-3.22)
{Crude ORs;
{Age adjusted ORs;
*p,0.05,
**p,0.01.
doi:10.1371/journal.pone.0021866.t004
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only.
Discussion
In Maharashtrian subjects, the observed frequencies for TGFB1
T29C polymorphism were comparable to those reported in North
Indian subjects [31]. Together these data reveal relatively higher
frequency of TGFB1*29C allele in western and northern Indians,
as compared to those of European descent [4,7,8]. Conversely,
another study in healthy subjects from South India [32] reporting
allele and genotype frequencies similar to those reported in Whites
might reflect extensive variation across ethnic groups, and thus
demands additional studies in diverse Indian population groups.
The TGFB1*29C allele frequency in Parsi controls was compara-
ble to that observed in their ancestral neighbors, the Iranian
controls (47% and 43%) as reported by two groups [41,42].
The strikingly lower frequency of TGFBR1*6A allele in
Maharashtrian women compared to that seen in Parsis [2.0% vs
6.8%, respectively; p,0.01; power-67%) is also in contrast to data
from Whites, where the frequency of this allele varies between six
and eleven percent [10]. Two studies in Chinese subjects have
reported disparate frequencies of 6.2% [43] and 11% [44] for this
allele. Thus the frequency of TGFBR1*6A allele observed in
Maharashtrian women in the present study is the lowest reported
so far.
Table 5. TGFBR1 6A/9A polymorphism and risk for breast cancer in Maharashtrian and Parsi women.
Maharashtrian Subjects Parsi Subjects
Cases/Controls OR
{ (95% CI) OR
{ (95% CI) Cases/Controls OR
{ (95% CI)
Genotype
TGFBR1 6A9A
Dominant Model
9A9A 163/213 1 1 33/148 1
9A9A/9A6A 4/9 0.58 (0.18-1.92) 0.83 (0.23-3.0) 9/21 1.92 (0.81-4.57)
Additive Model
9A9A 163/213 1 1 33/148 1
9A6A 4/9 0.58 (0.18-1.92) 0.83 (0.23-3.0) 8/19 1.89 (0.76-4.68)
6A6A 0/0 - - 1/2 2.24 (0.19-25.47)
Recessive Model
9A9A/9A6A 167/222 1 1 41/167 1
6A6A 0/0 - - 1/2 2.04 (0.18-23.01)
{Crude ORs;
{Age adjusted ORs.
doi:10.1371/journal.pone.0021866.t005
Table 6. Analysis of association between predicted ˆ TGF b signaling strength and risk for breast cancer.
Maharashtrian Subjects Parsi Subjects
Cases/Controls OR
{ (95% CI) OR
{ (95% CI) Cases/Controls OR
{ (95% CI)
Predicted Signaling Status
Dominant Model
HS 29/52 1 1 2/32 1
IS + LS 128/167 1.37 (0.83-2.29) 1.27 (0.74-2.2) 40/128 5 (1.15-21.79)*
Additive Model
HS 29/52 1 1 2/32 1
IS 126/160 1.41 (0.85-2.35) 1.29 (0.75-2.24) 31/111 4.47 (1.01-19.69)*
LS 2/7 0.51 (0.1-2.63) 0.66 (0.12-3.71) 9/17 8.47 (1.64-43.72)*
Recessive Model
HS + IS 155/212 1 1 33/143 1
LS 2/7 0.39 (0.08-1.91) 0.54 (0.10-2.87) 9/17 2.29 (0.94-5.59)
{Crude ORs;
{Age adjusted ORs;
*p#0.05;
**p#0.01.
HS - High Signalers: CC/9A9A; IS - Intermediate Signalers: TT/9A9A, CC/9A6A, CC/6A6A or TC/9A9A;
LS - Low Signalers: TT/6A6A, TT/9A6A, TC/9A6A or TC/6A6Aˆ(Ref. 30).
doi:10.1371/journal.pone.0021866.t006
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polymorphisms with breast cancer risk
Our findings in Maharashtrian premenopausal women suggest
an association between the presence of TGFB1*29C allele (45%
power), and a reduced risk for the disease especially in the younger
age group (,40 yrs; 72% power). These observations are in direct
contrast with those from the Breast Cancer Association Consor-
tium [4], a multicentric study that predominantly included subjects
of European descent from different continents. On the other hand,
our findings concur with the observations in premenopausal
Japanese women and in American women [27,30]. The protection
conferred by higher frequency of this allele associated with higher
TGF b production would be compatible with its ability to suppress
development of mammary tumors [10]. The possible contribution
of low frequency of the TGFBR1*6A allele to the observed effect of
the TGFB1*29C allele on the risk for the disease in Maharashtrian
women cannot be ruled out.
An attempt was also made to analyse the association of TGFB1
T29C genotypes with hormone receptor status in Maharashtrian
patients. Of the one hundred and twenty two patients where the
information was available, the hormone receptor negative tumor
bearing subjects were characterized by a strikingly lower frequency
of TGFB1*CC genotype compared to the hormone receptor
positive group (8 of 64 vs 10 of 40; Table S1). Thus a trend towards
an association between lower frequency of hormone receptor
negative tumors and TGFB1*CC genotype was suggested (p,0.05;
Fig S1). Similar findings have been reported by Kaklamani et al.
[30] in a cohort that included patients from all age groups.
The associations seen in our study however must be viewed with
caution in view of the inadequate power of our study (Table 3 &
4). The data from the Breast Cancer Association Consortium that
comprised of nearly thirteen thousand cases and fifteen thousand
controls revealed a 16% increased risk for rare homozygotes with
nearly 100% power [4]. The frequency of the minor allele for
TGFB1*T29C polymorphism varies from 38% to 44% in the
majority of populations across the world [9]. Thus, for the
dominant model, over three thousand patients and a similar
number of healthy controls would have to be studied in order to
detect a 15% increase in associated risk with adequate power (80%
at a=0.05) and, for the recessive model, over five thousand
patients and controls would have to be studied. Similarly, for an
equivalent increase in risk associated with TGFBR1*6A allele
(frequency 10%) with adequate power, sixteen thousand (domi-
nant model) and forty six thousand (recessive model) patients and
controls would have to be studied [40]. Accordingly, for
TGFB1*T29C polymorphism with the observed allele frequencies
in the western Indian population, to detect a 15% change in the
risk for breast cancer, nearly four thousand patients and an equal
number of healthy controls would be needed to achieve a power of
80% (at a=0.05). Similar computations for TGFBR1*6A allele
indicate that for a fifteen percent increment in the risk for breast
cancer [10] due to presence of this allele, nearly twenty thousand
patients and controls would be needed whereas, to determine its
effect recessively, over a million subjects would be needed. In view
of these considerations, the possibility that the observed association
in our study of western Indian women is a false positive result
cannot be ruled out.
TGF b1 signaling status and risk for breast cancer
An important consequence of the relatively higher frequency of
TGFB1*29C allele and lower frequency of TGFBR1*6A allele in
healthy Maharashtrian women was revealed when combinations
of these genotypes were analyzed. Categorization of individuals
into low, moderate and high TGF b1 signalers based on an
approach described by Kaklamani et al [30], revealed strikingly
lower frequency of low signalers in healthy Maharashtrian women
compared to that in Parsi women (3.2% vs 10.6%; p,0.01). A
comparison of the frequencies of high, intermediate and low
signalers among healthy subjects reported in literature (Fig 1)
indicates that the frequency of low signalers is strikingly reduced in
women from western India.
In view of the small numbers of patients studied from the Parsi
community, the observed high risk (OR .4) for breast cancer
indicated for low and intermediate (p=0.01 and p=0.05,
respectively; Table 6) signalers in these subjects warrants a note
of caution. The observation may reflect the high degree of genetic
homogeneity [36] and/or an ethnicity-specific effect [45]. Parsis
have been known to marry within the community for over the past
few centuries and may have experienced a genetic bottleneck
following their arrival in Indian seven hundred years ago [35].
Basis for the prevalence of TGF b signaling mediated
inhibition in Maharashtrian women and its implications
Several lines of evidence prompt us to suggest that the distinct
trends in genotype and allele frequencies of the two polymor-
phisms in Maharashtrians may reflect the effect of environmental
forces. A higher frequency of genotypes contributing to elevated
pro-inflammatory responses has been reported in populations from
tropical regions [46,47]. Commensurate with these observations,
Asians are characterized by higher levels of markers associated
with chronic inflammation as well as IgG1 levels, as compared
to Whites [48,49]. In view of the significant contribution of
inflammation to the initiation and progression of malignancies
[50], these features may also contribute to an overall earlier age of
onset of malignant disorders in the region [51]. The prevalence of
TGF b mediated inhibition in Maharashtrian subjects revealed in
this study may have emerged as a counteracting force to the
selection of the pro-inflammatory genotypes to minimize the risk
of autoimmunity [52]. This in turn could also suppress the
development of malignancies by virtue of its anti-proliferative
effects on the mammary epithelial cells [21]. Thus, the effects of
higher frequency of TGFB1*29C allele, alone and in association
Figure 1. Comparison of frequencies of High, Intermediate and
Low signalers in various studies reported so far. Numbers in
parentheses represent the number of healthy subjects studied in each
report.
doi:10.1371/journal.pone.0021866.g001
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implications for the lower incidence of breast cancer in this
population.
The large body of data supporting the association of TGFB1
T29C and TGFBR1 6A/9A polymorphisms with the risk for breast
cancer provides a strong basis to endorse the view that the
combinations of genotypes resulting in weak TGF b signaling
would have a greater impact on the risk for the disease - although
the findings of epidemiological studies in this context remain
equivocal [24,25,30]. Therefore, the population attributable risk
associated with such genotype combinations or their contribution
to the total disease burden, a function of frequency and penetrance
also remains unresolved. Our results implicate TGFB1*29C
genotype in modulating the risk for breast cancer in western
Indian women. Further this population is characterized by a lower
frequency of TGFBR1*6A allele. These observations, and the
predicted influence of the combination of genotypes of the two
polymorphisms studied, permit us to argue that three-fold lower
frequency of low signalers may represent one of the mechanisms
that would contribute to the reduced risk for breast cancer in
Maharashtrian women compared to Parsis or Whites, a possibility
that would be commensurate with the known difference in breast
cancer incidence rates between the Indians and Whites [53].
In summary, the present study on TGFB1 T29C and TGFBR1
6A/9A polymorphisms in relation to breast cancer risk has
revealed important differences between the genotypes and allele
frequencies in premenopausal Maharashtrian women, compared
to Parsi and White women. These may have implications for the
lower risk for the disease in Maharashtrian women. Available data
supports the possibility of environmental influence as one of the
driving forces giving rise to such an ethnicity-specific genetic
variation [46,47]. The influence of high TGF b1 producing
genotype (TGFB1*CC) in western Indian women suggested by our
study and in White women by others [4], despite opposite trends,
points towards its considerable penetrance. The trends revealed in
the present study raise a number of important possibilities and
stress need for a larger study coupled with the assessment of
clinical data. Such a study could also provide a valuable prognostic
parameter, especially in the context of earlier age of onset and
prevalence of an aggressive disease in Indian patients.
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